BIOCON 1. Assuming Biocon receives approval for BioMab‚ should it launch the drug immediately or conduct phase 3 trials before launch? Elaborate on the various elements of your action plan. 2. How big is the current and future market opportunity in BIOMAb? The current market opportunity of BIOMAb is limited but the future is going to be bigger. In 2004‚ the 5-year prevalence (number of people diagnosed with cancer and still alive after 5 years) was 375‚000 and the incidence (new cases
Premium Oncology Cancer Chemotherapy
wonderful job striking a balance between their house and career. Here are a few: DR. KIRAN MAZUMDAR SHAW Dr. Kiran Mazumdar-Shaw‚ Chairman & Managing Director of Biocon Ltd.‚ who became India’s richest woman in 2004‚ was educated at the Bishop Cotton Girls School and Mount Carmel College in Bangalore. She founded Biocon India with a capital of Rs.10‚000 in her garage in 1978 – the initial operation was to extract an enzyme from papaya. Her application for loans were turned down by banks then
Premium Dhirubhai Ambani Mukesh Ambani Reliance Industries
Biocon Ltd. Building a Biotech Powerhouse Case analysis -Rajdeep Desai Introduction: Established in 1978‚ Biocon Limited is Asia’s premier biotechnology company and India’s largest biotechnology company by revenue. It is the only Asian company among the top 25 in global biopharma. Biocon is called as Poster child of Biotech in India. The Group‚ promoted by Ms. Kiran Mazumdar Shaw‚ is a fully-integrated‚ innovation-driven healthcare enterprise with strategic focus on biopharmaceuticals and
Premium Clinical trial Biotechnology Pharmaceutical industry
Biocon Limited 1. Assuming Biocon receives approval for BioMAb‚ should it launch the drug immediately or conduct phase 3 trials before launch? Elaborate the various elements of your action plan. Even if the Drug Controller General of India (DCGI) grants permission for BIOMAb in fall 2006‚ Biocon should still conduct phase 3 trials before launching. Both Biocon and Clinigene are new to the industry and strong reputations have yet to be developed. Therefore‚ Biocon must means make sure BIOMAb
Premium Oncology Cancer Chemotherapy
Biocon: Launching a New Cancer Drug in India Section E Group 5 Ankita Khandelwal (255) Bojja Raghavendar Reddy (265) Hitesh Chopra (275) Nikhil Singh Rawat (285) Raghavan K. V. (295) Vaibhav Saxena (305) Situation Analysis: • Biocon is an Indian Drug company that has evolved over the years: ▪ It was an enzyme manufacturer for food industry and developed expertise
Premium Oncology Cancer Chemotherapy
an Indian public-listed company BIOCON Final Project Report Contents Background 3 Subsidiary Companies 4 Products and Services 4 The Auditors report 5 The Director’s Report 6 Accounting Policies 7 Balance sheet 14 Cash flow analysis 18 ANNEXURES 21 Ratio Analysis 23 New Terminologies 29 References 30 Background Established in 1978‚ Biocon is India ’s premier biotechnology company. Headquartered in Bangalore Biocon has evolved from an enzyme company
Premium Balance sheet Asset Income statement
Strength: The strengths of Biocon are * Financial Leverage – Biocon has maintained a constant Debt/ Equity ratio between 0.11-0.12[1] in the last 5 years‚ which gives it a financial leverage‚ thus letting the share holders enjoy the earnings and also makes the organization financially strong. * Skills in Enzymes – Biocon with its recombinant DNA technology has managed to achieve a different share in the industry‚ its products like Insugen from recombinant human DNA‚ BIOMAb EGFR India’s first anti
Premium Biotechnology DNA Chemotherapy
Biocon Case Assignment Questions 1. Assuming Biocon receives approval for BIOMAb‚ should it launch the drug immediately or conduct phase 3 trials before launch? Elaborate the various elements of your action plan. If Biocon receives approval for BIOMAb‚ the management team will need to carefully consider what the best course of action is moving forward. If the company elects to launch the drug immediately‚ they will be able to have the first mover advantage‚ reaching the market before their
Premium Pharmaceutical industry Oncology First-mover advantage
Corporate Social Responsibility While Biocon was involved in community programs from inception‚ it started a corporate social responsibility wing—the Biocon Foundation—in 2004 through which it works in the areas of health‚ education and infrastructure‚ especially in rural areas. Health Through the Arogya Raksha Yogana (ARY) clinics‚ Biocon helps meet the primary‚ tertiary and secondary healthcare needs of various communities. Its 7 ARY clinics—located where healthcare facilities are poor—offer
Premium Hygiene Karnataka Sanitation
Q. Explain the Evolution of Organization Theory with reference to Life-Cycle Perspective Growth phase. (Biological Metaphor/ Organizations as Living Beings) {Refer Growth- Gareth Jones/ Decline-R. Daft/ PLC-Chs. 2‚17- Stephen Robbins} a.) A Life-Cycle refers to a pattern of predictable change. There are distinct stages‚ through which organizations proceed. Research on the organization life-cycle leads us to a five-stage model. a. Entrepreneurial Stage: The organization is in its infancy. Goals
Premium Organization Formal system Organizational studies and human resource management